The L3T4 molecule is part of the helper T-cell antigen/Ia recognition complex

The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands

One hypothesis seeking to explain the signaling and biological properties of T cell receptor for antigen (TCR) partial agonists and antagonists is the coreceptor density/kinetic model, which proposes that the pharmacologic behavior of a TCR ligand is largely determined by the relative rates of (a) dissociation ofligand from an engaged TCR and (b) recruitment oflck-linked coreceptors to this ligand-engaged receptor. Using several approaches to prevent or reduce the association of CD4 with occupied TCR, we demonstrate that consistent with this hypothesis, the biological and biochemical consequence of limiting this interaction is to convert typical agonists into partial agonist stimuli. Thus, adding anti-CD4 antibody to T cells recognizing a wild-type peptide-MHC class II ligand leads to disproportionate inhibition of interleukin-2 (IL-2) relative to IL-3 production, the same pattern seen using a TCR partial agonist/antagonist. In addition, T cells exposed to wild-type ligand in the presence of anti-CD4 antibodies show a pattern of TCR signaling resembling that seen using partial agonists, with predominant accumulation of the p21 tyrosine-phosphorylated form of TCR-zeta, reduced tyrosine phosphorylation of CD3epsilon, and no detectable phosphorylation of ZAP-70. Similar results are obtained when the wild-type ligand is presented by mutant class II MHC molecules unable to bind CD4. Likewise, antibody coligation of CD3 and CD4 results in an agonist-like phosphorylation pattern, whereas bivalent engagement of CD3 alone gives a partial agonist-like pattern. Finally, in accord with data showing that partial agonists often induce T cell anergy, CD4 blockade during antigen exposure renders cloned T cells unable to produce IL-2 upon restimulation. These results demonstrate that the biochemical and functional responses to variant TCR ligands with partial agonist properties can be largely reproduced by inhibiting recruitment of CD4 to a TCR binding a wild-type ligand, consistent with the idea that the relative rates of TCR-ligand disengagement and of association of engaged TCR with CD4 may play a key role in determining the pharmacologic properties of peptide-MHC molecule ligands. Beyond this insight into signaling through the TCR, these results have implications for models of thymocyte selection and the use of anti-coreceptor antibodies in vivo for the establishment ofimmunological tolerance.

Growth regulation of a T-cell lymphoma via the T-cell receptor

Autocrine stimulation is described for a Radiation leukaemia virus (RadLV)-induced T-cell lymphoma, C6VL/1. The proliferation of this tumour cell line can be regulated by several agents, including interleukin-2 (IL-2), antibodies to the IL-2 receptor and the T-cell antigen-specific receptor (TCR), as well as RadLV retrovirus particles produced by the cell itself. This information has been gained using various procedures to slow or arrest C6VL/1 proliferation, including the addition of gamma interferon (gamma-IFN) and cell culture at low density. All data suggest that these cells can receive growth stimulation via the T-cell receptor (TCR) and IL-2 receptor, implicating autocrine stimulation of growth involving IL-2 and retroviral gene products.

Physical association of CD4 and the T-cell receptor can be induced by anti-T-cell receptor antibodies

CD4 can physically associate with the CD3-T-cell receptor complex as visualized in cocapping experiments. This association occurs when the T-cell receptor is cross-linked by certain anti-variable region antibodies that appear to induce a conformational change in the receptor such that it associate with CD4. Similar association has been observed in earlier studies with the same cloned helper T cell when the physiological ligand, antigen-class II major histocompatibility complex molecule, is bound by the T-cell receptor. The ability of anti-T-cell receptor antibodies to induce the T-cell receptor-CD4 association correlates with a 100-fold increase in the ability of the antibody to activate the T cell. This suggests that the complex of CD4 and the T-cell receptor act synergistically in T-cell activation, thus readily explaining the commonly observed association of CD4 expression with class II major histocompatibility complex-restricted antigen recognition. This association could also play a role in infection by human immunodeficiency virus.

Inhibition of the responses of a cloned CD4+ T cell line to different class II major histocompatibility complex ligands by anti-CD4 and by anti-receptor Fab fragments are directly related

The responses of a single cloned T cell line to three different class II major histocompatibility complex (MHC) ligands have been compared for avidity, determined by inhibition with anti-T cell receptor Fab fragments directed at two different receptor epitopes, and for ease of inhibition with anti-CD4 antibody. It has, thus, been directly demonstrated that ease of inhibition of the response of a T cell to a class II MHC ligand by anti-CD4 is inversely related to the avidity of the T cell receptor for that ligand. The difficulties in inferring from this finding that CD4 acts primarily by increasing receptor avidity for its class II MHC ligand are discussed in the light of evidence suggesting that CD4 is an active signaling component of the T cell receptor for class II MHC ligands.

Expression and function of CD8 in a murine T cell hybridoma

In general, the human CD8 molecule is expressed on T cells specific for HLA class I molecules. Studies designed to delineate the function and to define the ligand of the CD8 molecule have been complicated by the fact that the presumptive ligand for CD8 is on the HLA class I molecule, the same molecule encoding the ligand for the antigen-specific T cell receptor. The ability to express genes in cells other than their natural host has produced a new technology with which to approach CD8 functional studies. The insertion of a cDNA clone for CD8 in a defective retroviral vector has allowed the transfer of CD8 by infection with the resulting defective retrovirus. CD8 was then expressed in an HLA class II-specific T cell, thus separating the ligand requirements of the TCR and CD8. By this approach, the human CD8 molecule was expressed in a murine T cell hybridoma specific for human class II antigens. The resulting CD8+ hybridomas demonstrated a 10-fold increase in IL-2 production over the parent cell line when stimulated with JY, a human B lymphoblastoid cell line expressing both class I and II HLA antigens, demonstrating that expression of CD8 increases T cell activation. mAbs directed against the CD8 molecule inhibited the response of CD8+ hybridomas to JY, supporting the conclusion that the CD8 molecule was fractional. The role of CD8 as a receptor for class I MHC antigens was addressed by stimulation with a cell line expressing HLA-DR antigens, but lacking the expression of HLA class I antigens (Daudi). Stimulation of the CD8+ hybridomas by Daudi did not result in increased IL-2 production. The response to Daudi was unaltered by the addition of anti-CD8 mAb, in contrast to the ability of anti-CD8 mAb to block JY stimulation. Furthermore, mAbs directed against the class I antigens present on JY cells were able to block the enhanced response of the CD8+ hybridomas to JY. These data support the hypothesis that HLA class I molecules are the ligands involved in the CD8-dependent enhancement of T cell activation.

Coclustering of CD4 (L3T4) molecule with the T-cell receptor is induced by specific direct interaction of helper T cells and antigen-presenting cells

Blocking studies with monoclonal antibodies have suggested that helper T cell recognition and triggering involve the CD4 (L3T4) accessory molecule as well as the T-cell receptor (TCR) that is linked to the T3 complex. We have investigated the surface distribution of L3T4 and TCR during the direct interaction of a cloned murine helper T-cell line with an antigen-presenting B-cell line. Using immunofluorescence microscopy, we show that in 1:1 cell couples formed between the two cells, in which a specific interaction can be demonstrated, the L3T4 and the TCR become redistributed on the T-cell surface so that they are concentrated in the cell-cell contact region. This coclustering of L3T4 with TCR occurs only when the relevant antigen and appropriate major histocompatibility class II molecules are presented to the T cell, and it therefore requires the specific interaction of the TCR with its complex ligand on the antigen-presenting cell.

A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus

We show here that the interaction of a radiation leukemia virus-induced thymoma, C6VL, with its cognate retroviruses occurs in the vicinity of the T cell receptor (TCR). While an anti-clonotypic antibody completely inhibits this interaction, antibodies specific for another T cell receptor complex determinant, L3T4, only partially inhibit the cell-retrovirus interaction. Several antibodies to more abundant cell-surface determinants (T200, Ly15, H-2Db) do not inhibit this interaction. Under capping conditions, either of the antibodies to L3T4 or TCR epitopes modulate virus binding receptors from the surface of C6VL/1 cells. L3T4 and the TCR do not comodulate significantly on the surface of C6VL/1 cells. These experimental findings implicate the existence of rare TCR-L3T4 complexes on C6VL/1 cells, and the involvement of these complexes in the binding of C6VL/1 to its cognate retrovirus. In addition, the clonotypic anti-TCR antibody inhibits C6VL/1 cell proliferation at concentrations that block its binding to its produced retroviruses.